As of 2026-09-13, the Relative Valuation of Kymera Therapeutics Inc (KYMR) is (97.24) USD. This relative valuation is based on P/E multiples. With the latest stock price at 114.96 USD, the upside of Kymera Therapeutics Inc based on Relative Valuation is -184.6%.
The range of the Relative Valuation is (85.23) - (108.17) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 23.3x - 29.7x | 26.5x |
| Forward P/E multiples | 23.4x - 30.4x | 26.9x |
| Fair Price | (85.23) - (108.17) | (97.24) |
| Upside | -174.1% - -194.1% | -184.6% |
| Date | P/E |
| 2026-09-10 | -32.12 |
| 2026-09-09 | -31.69 |
| 2026-09-08 | -31.98 |
| 2026-09-04 | -32.23 |
| 2026-09-03 | -32.20 |
| 2026-09-02 | -32.57 |
| 2026-09-01 | -32.69 |
| 2026-08-31 | -32.62 |
| 2026-08-28 | -32.44 |
| 2026-08-27 | -33.01 |
| 2026-08-26 | -34.47 |
| 2026-08-25 | -34.77 |
| 2026-08-24 | -33.24 |
| 2026-08-21 | -32.89 |
| 2026-08-20 | -33.36 |
| 2026-08-19 | -34.95 |
| 2026-08-18 | -33.33 |
| 2026-08-17 | -33.33 |
| 2026-08-14 | -32.23 |
| 2026-08-13 | -31.42 |
| 2026-08-12 | -31.31 |
| 2026-08-11 | -30.10 |
| 2026-08-10 | -29.81 |
| 2026-08-07 | -29.52 |
| 2026-08-06 | -29.22 |
| 2026-08-05 | -28.96 |
| 2026-08-04 | -28.66 |
| 2026-08-03 | -27.54 |
| 2026-07-31 | -28.39 |
| 2026-07-30 | -29.38 |
| 2026-07-29 | -28.90 |
| 2026-07-28 | -29.15 |
| 2026-07-27 | -30.22 |
| 2026-07-24 | -30.36 |
| 2026-07-23 | -30.31 |
| 2026-07-22 | -30.30 |
| 2026-07-21 | -31.13 |
| 2026-07-20 | -30.49 |
| 2026-07-17 | -31.79 |
| 2026-07-16 | -31.30 |
| 2026-07-15 | -31.33 |
| 2026-07-14 | -30.77 |
| 2026-07-13 | -30.31 |
| 2026-07-10 | -32.77 |
| 2026-07-09 | -32.67 |
| 2026-07-08 | -31.34 |
| 2026-07-07 | -32.74 |
| 2026-07-06 | -31.51 |
| 2026-07-02 | -31.17 |
| 2026-07-01 | -31.36 |